预防医学

订阅

MedSci主页 / 所有栏目 / 预防医学

Clinica Chimica Acta：川崎病患儿生长分化因子-15浓度会发生如何变化？

2020-06-24 MedSci原创 MedSci原创

川崎病
关注

在此，研究人员对急性川崎病(KD)患儿血清中生长分化因子-15 (growth differentiation factor-15, GDF-15)的浓度进行研究，并评价其在预测冠状动脉病变作用

在此，研究人员对急性川崎病(KD)患儿血清中生长分化因子-15 (growth differentiation factor-15, GDF-15)的浓度进行研究，并评价其在预测冠状动脉病变(CALs)和无反应KD中的作用。

研究人员收集了30名健康儿童和131名KD患儿在静脉注射免疫球蛋白治疗前的血样。采用ELISA试剂盒检测血清GDF-15浓度。采用单因素和多因素logistic回归分析，评估GDF-15与CALs的发生和治疗反应之间的潜在相关性。

研究结果显示，与健康对照组相比，KD组血清GDF-15浓度显著升高。与无CALs相比，无CALs时KD的血清GDF-15浓度也升高，无应答时KD的血清GDF-15浓度也升高，无应答时KD的血清GDF-15浓度也升高。血清中GDF-15浓度与KD患者的白细胞计数、c -反应蛋白(CRP)、血沉率(ESR)呈正相关，与白蛋白、前白蛋白呈负相关。GDF-15是CALs和无反应KD的独立预测因子。GDF-15预测CALs优于CRP和ESR，而在预测CALs方面不逊于CRP和ESR的组合。

研究结果表明，急性KD患者血清GDF-15浓度明显升高，其中CALs患者血清GDF-15浓度升高明显，无应答KD患者血清GDF-15浓度升高明显。GDF-15可作为CALs及无应答KD的独立预测因子。

原始出处：

Gang Li,Ting Wang,Increased concentrations of growth differentiation factor-15 in children with Kawasaki disease

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849958, encodeId=18bb1849958fb, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Sep 04 06:41:23 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040050, encodeId=020d2040050ee, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 08 21:41:23 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544649, encodeId=3ada1544649b1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:41:23 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2020-09-04 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849958, encodeId=18bb1849958fb, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Sep 04 06:41:23 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040050, encodeId=020d2040050ee, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 08 21:41:23 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544649, encodeId=3ada1544649b1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:41:23 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2021-05-08 guoyibin

    #生长分化因子-15#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849958, encodeId=18bb1849958fb, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Sep 04 06:41:23 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040050, encodeId=020d2040050ee, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 08 21:41:23 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544649, encodeId=3ada1544649b1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:41:23 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2020-06-26 12498974m55暂无昵称

    #浓度#

    0

相关资讯

Ann Rheum Dis：类似于川崎病，与SARS-CoV-2相关的儿童多系统炎性综合征（Kawa-COVID-19）

Kawa-COVID-19可能代表了一种时间上与SARS-CoV-2感染相关的新型全身性炎症综合征。

疑与新冠相关的儿童“怪病”，韩国也开始出现

据韩联社5月26日报道，韩国中央防疫对策本部当日通报，

BMJ：法国儿童新冠肺炎患者川崎样多系统炎症综合征特征研究

研究认为，巴黎地区儿童和青少年川崎样多系统炎症综合征的持续爆发可能与SARS-CoV-2有关。大多数患儿有胃肠道症状，川崎病休克综合征，为非洲血统

Lancet：新冠肺炎疫情期间需警惕儿童川崎病风险

新冠肺炎流行期间，意大利Bergamo地区的川崎病的发病率增加了30倍，且疫情期间患儿的年龄较大，心脏受累率较高并有巨噬细胞活化综合征特征。

Lancet：静脉注射免疫球蛋白联合环孢素治疗高耐药风险川崎病

研究认为，静脉注射免疫球蛋白联合环孢素可有效治疗免疫球蛋白耐药高风险的川崎病患者

川崎病患儿的TNF-α阻滞剂干预与安慰剂或其他治疗的比较

川崎病（Kawasaki disease，KD）是一种急性血管炎症，主要影响6个月至5岁的儿童。川崎病的标准医疗管理包括静脉注射丙种球蛋白（IVIG）加阿司匹林。这种标准治疗通常是有效的，但对大约15%-20%的儿童无效。当治疗无效时，儿童可能会患上严重的心脏病。最近，研究人员发现，肿瘤坏死因子-α（TNF-α）阻断剂可能对标准疗法尚未治愈的川崎病儿童有效。然而，我们仍然不清楚TNF-α阻滞剂治疗